Alexza Pharmaceuticals, Inc. announced a private placement equity offering of 8.1 million shares of common stock to several qualified institutional investors. The company will receive $2.4325 per share, or approximately $19.1 million in net proceeds.
Alexza Pharmaceuticals also issued 7.3 million warrants as part of the deal. The warrants entitle the holder to purchase 0.9 shares of common stock at $2.77 per share. The warrants expire in seven years.
Alexza Pharmaceuticals is developing a proprietary drug delivery technology called the Staccato® system. This technology vaporizes unformulated pharmaceutical drugs into an aerosol form that allows rapid systemic delivery through lung inhalation.
Alexza Pharmaceuticals has completed Phase 3 trials for using this technology to deliver Loxapine for use in treating schizophrenic or bipolar disorder patients. The company plans a new drug application submission in 2010.
Staccato® is also being tested for use in other areas, including the treatment of migraine headaches, pain and insomnia.